Skip to main content
. 2020 Jan 13;135(9):680–688. doi: 10.1182/blood.2019002959

Figure 3.

Figure 3.

Effect of FLT3-ITD on outcome according to pretransplant MRD status. (A) HR and 95% CIs for FLT3-ITD mutation in each group. (B-D) OS from transplant for patients with high (B), low (C), and negative (D) pretransplant MRD. Percentages indicate estimated 2y-OS.